Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMRXB74)

• Drug Name: ARISTEROMYCIN Drug Info
• Synonyms: 19186-33-5; 3-(6-aminopurin-9-yl)-5-(hydroxymethyl)cyclopentane-1,2-diol; NSC613806; NSC615828; NSC613807; NSC103526; Carbocyclic Lyxo-A; Carbocyclic Xylo-A; AC1Q4VH0; Cyclaradine Carbocyclic Ara A; SCHEMBL9820408; AC1L1D83; CTK4E0829; 3-(6-amino-9h-purin-9-yl)-5-(hydroxymethyl)cyclopentane-1,2-diol; NSC-613807; NSC-613806; NSC-615828; NSC-103526; J-012404; 1,2-Cyclopentanediol,5-(6-amino-9H-purin-9-yl)-3-(hydroxymethyl)-, (1S,2R,3R,5R)-
• Cross-matching ID:
  PubChem CID: 65269
  CAS Number: CAS 19186-33-5
  TTD Drug ID: DMRXB74

Molecule-Related Drug Atlas

Drug(s) Targeting Adenosylhomocysteinase (AHCY)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Nicotinamide-Adenine-Dinucleotide	DM9LRKB	N. A.	N. A.	Investigative	[3]
2-Propanol, Isopropanol	DML5O0H	Discovery agent	N.A.	Investigative	[4]
Neplanocin A	DMXULGK	Discovery agent	N.A.	Investigative	[5]
5'-deoxy-5'-ureidoadenosine	DM8IQX4	Discovery agent	N.A.	Investigative	[6]
5(E)-(5'-Deoxyadenosin-5'-ylidene)pentanoic acid	DM1IGOD	Discovery agent	N.A.	Investigative	[7]
5-methylenearisteromycin	DMIQ1X3	Discovery agent	N.A.	Investigative	[2]
NORARISTEROMYCIN	DMZ9024	Discovery agent	N.A.	Investigative	[8]
D-Eritadenine	DM2XT7S	N. A.	N. A.	Investigative	[3]
5'-S-ethyl-5'-thioadenosine	DM0PQH1	Discovery agent	N.A.	Investigative	[4]
FLUORO-NEPLANOCIN A	DM0LR7G	Discovery agent	N.A.	Investigative	[9]

Drug(s) Targeting Adenosine A2a receptor (ADORA2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Caffeine	DMKBJWP	Orthostatic hypotension	BA21	Approved	[10]
Istradefylline	DM20VSK	Parkinson disease	8A00.0	Approved	[11]
Regadenoson	DM76VHG	Radionuclide imaging	N.A.	Approved	[12]
Tozadenant	DMATC14	Parkinson disease	8A00.0	Phase 3	[13]
Binodenoson	DMVHF8G	Hypertension	BA00-BA04	Phase 3	[14]
Apadenoson	DMD8QTC	Coronary artery disease	BA80	Phase 3	[15]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[16]
Dexefaroxan	DMTY4KN	Parkinson disease	8A00.0	Phase 2	[17]
AMP-579	DMJ4GPR	Hyperlipidaemia	5C80	Phase 2	[18]
BIIB014	DMH7RJ1	Parkinson disease	8A00.0	Phase 2	[19]

Drug(s) Targeting Adenosine A1 receptor (ADORA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Caffeine	DMKBJWP	Orthostatic hypotension	BA21	Approved	[10]
Rolofylline	DMSZPR3	Heart failure	BD10-BD13	Phase 3	[20]
Tonapofylline	DMBH316	Acute and chronic heart failure	BD1Z	Phase 2	[16]
AMP-579	DMJ4GPR	Hyperlipidaemia	5C80	Phase 2	[18]
SELODENOSON	DMQM3IX	Cardiac arrhythmias	BC9Z	Phase 2	[21]
Apaxifylline	DMQMV9F	Cognitive impairment	6D71	Phase 2	[22]
SLV320	DM867BJ	Heart failure	BD10-BD13	Phase 2	[23]
DTI-0009	DMV84OK	Atrial fibrillation	BC81.3	Phase 2	[21]
Capadenoson	DMYWO62	Atrial fibrillation	BC81.3	Phase 2	[24]
BAY 1067197	DM4JGNH	Heart failure	BD10-BD13	Phase 2	[25]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adenosine A1 receptor (ADORA1)	TTK25J1	AA1R_HUMAN	Inhibitor	[1]
Adenosine A2a receptor (ADORA2A)	TTM2AOE	AA2AR_HUMAN	Inhibitor	[1]
Adenosylhomocysteinase (AHCY)	TTE2KUJ	SAHH_HUMAN	Inhibitor	[2]

References

• [1] Methanocarba analogues of purine nucleosides as potent and selective adenosine receptor agonists. J Med Chem. 2000 Jun 1;43(11):2196-203.
• [2] Synthesis of 2-modified aristeromycins and their analogs as potent inhibitors against Plasmodium falciparum S-adenosyl-L-homocysteine hydrolase. Bioorg Med Chem. 2008 Apr 1;16(7):3809-15.
• [3] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [4] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [5] Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res. 1993 Sep;22(1):45-75.
• [6] Design, synthesis, and molecular modeling studies of 5'-deoxy-5'-ureidoadenosine: 5'-ureido group as multiple hydrogen bonding donor in the active ... Bioorg Med Chem Lett. 2007 Aug 15;17(16):4456-9.
• [7] Synthesis of 5'-functionalized nucleosides: S-Adenosylhomocysteine analogues with the carbon-5' and sulfur atoms replaced by a vinyl or halovinyl u... Bioorg Med Chem. 2008 May 15;16(10):5424-33.
• [8] Synthesis of 4'-modified noraristeromycins to clarify the effect of the 4'-hydroxyl groups for inhibitory activity against S-adenosyl-L-homocystein... Bioorg Med Chem Lett. 2008 Apr 15;18(8):2615-8.
• [9] Synthesis of 5'-substituted fluoro-neplanocin A analogues: importance of a hydrogen bonding donor at 5'-position for the inhibitory activity of S-a... Bioorg Med Chem Lett. 2004 Nov 15;14(22):5641-4.
• [10] Caffeine as a psychomotor stimulant: mechanism of action. Cell Mol Life Sci. 2004 Apr;61(7-8):857-72.
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [12] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [13] Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Lancet Neurol. 2014 Aug;13(8):767-76.
• [14] Coronary circulation responses to binodenoson, a selective adenosine A2A receptor agonist. Am J Cardiol. 2007 Jun 1;99(11):1507-12.
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3290).
• [16] 2-Amino-5-benzoyl-4-phenylthiazoles: Development of potent and selective adenosine A1 receptor antagonists. Bioorg Med Chem. 2010 Mar 15;18(6):2195-2203.
• [17] The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
• [18] Adenosine A1/A2a receptor agonist AMP-579 induces acute and delayed preconditioning against in vivo myocardial stunning. Am J Physiol Heart Circ Physiol. 2004 Dec;287(6):H2746-53.
• [19] Novel pharmacological targets for the treatment of Parkinson's disease. Nat Rev Drug Discov. 2006 Oct;5(10):845-54.
• [20] Association between the PDE4D gene and ischaemic stroke in the Chinese Han population. Clin Sci (Lond). 2009 Aug 17;117(7):265-72.
• [21] Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta. 2011 May;1808(5):1290-308.
• [22] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004779)
• [23] Role of matrix metalloproteinases and their tissue inhibitors as potential biomarkers of left ventricular remodelling in the athlete's heart. Clin Sci (Lond). 2009 Jul 16;117(4):157-64.
• [24] A1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs. 2008 Dec;17(12):1901-10.
• [25] Separation of on-target efficacy from adverse effects through rational design of a bitopic adenosine receptor agonist. Current Issue vol. 111 no. 12 Celine Valant, 4614-4619.